CN118119377A - 制剂 - Google Patents

制剂 Download PDF

Info

Publication number
CN118119377A
CN118119377A CN202280070135.8A CN202280070135A CN118119377A CN 118119377 A CN118119377 A CN 118119377A CN 202280070135 A CN202280070135 A CN 202280070135A CN 118119377 A CN118119377 A CN 118119377A
Authority
CN
China
Prior art keywords
antibody
buffer
stable liquid
liquid formulation
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280070135.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·皮尔布姆
M·J·E·布南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CN118119377A publication Critical patent/CN118119377A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202280070135.8A 2021-10-21 2022-10-20 制剂 Pending CN118119377A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2115121.2 2021-10-21
GBGB2115121.2A GB202115121D0 (en) 2021-10-21 2021-10-21 Formulations
PCT/EP2022/079182 WO2023067049A1 (en) 2021-10-21 2022-10-20 Formulations

Publications (1)

Publication Number Publication Date
CN118119377A true CN118119377A (zh) 2024-05-31

Family

ID=78806158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280070135.8A Pending CN118119377A (zh) 2021-10-21 2022-10-20 制剂

Country Status (17)

Country Link
US (1) US20240415769A1 (https=)
EP (1) EP4419078A1 (https=)
JP (1) JP2024539265A (https=)
KR (1) KR20240099311A (https=)
CN (1) CN118119377A (https=)
AR (1) AR127421A1 (https=)
AU (1) AU2022372646A1 (https=)
CA (1) CA3235381A1 (https=)
CL (1) CL2024001229A1 (https=)
CO (1) CO2024006193A2 (https=)
GB (1) GB202115121D0 (https=)
GE (2) GEAP202416520A (https=)
IL (1) IL312207A (https=)
MX (1) MX2024004872A (https=)
PE (1) PE20241193A1 (https=)
TW (1) TW202323288A (https=)
WO (1) WO2023067049A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
AU2022372646A1 (en) 2024-06-06
GEAP202416520A (en) 2024-07-25
AR127421A1 (es) 2024-01-24
GB202115121D0 (en) 2021-12-08
GEP20257800B (en) 2025-09-25
JP2024539265A (ja) 2024-10-28
TW202323288A (zh) 2023-06-16
CA3235381A1 (en) 2023-04-27
KR20240099311A (ko) 2024-06-28
US20240415769A1 (en) 2024-12-19
MX2024004872A (es) 2024-05-06
PE20241193A1 (es) 2024-06-03
IL312207A (en) 2024-06-01
EP4419078A1 (en) 2024-08-28
CL2024001229A1 (es) 2024-09-13
CO2024006193A2 (es) 2024-05-30
WO2023067049A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US20110256135A1 (en) Anti-nerve growth factor (ngf) antibody compositions
WO2020259605A1 (zh) 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
JP7475335B2 (ja) Ｃｓｆ－１ｒ抗体製剤
US20180008707A1 (en) Stable liquid formulation for monoclonal antibodies
JP2016525139A (ja) 安定化された抗体組成物
CN104066448A (zh) 眼病的治疗
WO2006004736A2 (en) Stable liquid and lyophilized formulation of proteins
US20240342083A1 (en) Anti-pd-1 antibody pharmaceutical composition and use thereof
KR20200089282A (ko) 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
AU2021272212A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
KR20240109250A (ko) 항ox40 단일클론 항체를 포함하는 약학적 제제
WO2020088492A1 (zh) 含有抗pcsk9抗体的稳定制剂
CN118119377A (zh) 制剂
CA3239182A1 (en) Stable antibody preparation
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
HK40109650A (zh) 制剂
CN118175989A (zh) 制剂
HK40109619A (zh) 制剂
HK40118051A (zh) Csf-1r抗体制剂
HK40107164A (zh) Csf-1r抗体制剂
CN119367531A (zh) 抗cd3×cd20双特异性抗体的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109650

Country of ref document: HK